お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は、ワクチンアジュバントの世界市場、容量、生産量、収益、価格の概要を紹介します。2019~2023年の歴史的な市場収益/売上データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。本レポートはメーカー、地域、製品の種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、製品タイプとアプリケーション/端末業界別にワクチンアジュバント市場を分類しています。
本レポートでは世界のワクチンアジュバント市場の主な参加者として、企業概要、販売数量、収益、価格、粗利益率、ポートフォリオ、地理的位置、重要な発展を次のパラメータに基づいて紹介します。本研究に含まれる主な企業は：GSK、CSL Limited、Croda、SEPPIC、Sanofi、Zhifei Biological、Escon、Huanuotai Biological、Rico Bio、SDA BIO、SPI Pharma、Phibro Animal Health、Vertellus

レポートはワクチンアジュバントの主要生産者を調査し、主要地域や国の消費状況も提供します。ワクチンアジュバントの今後の市場の可能性のハイライト、およびこの市場をさまざまなセグメントおよびサブセグメントに予測するための主要な地域/国の焦点。アメリカとカナダ、中国、アジア、ヨーロッパ、中東、アフリカ、ラテンアメリカ、およびその他の国の国別データと市場価値分析。

2019年から2030年までのタイプ別および用途別、売上高、収益、価格別のセグメントデータを分析します。
タイプ別市場セグメント：
    Emulsion Adjuvants
    Mineral Adjuvants
    Others

用途別の市場セグメント：
    Human Vaccine
    Veterinary Vaccine

本レポートの詳細内容
本レポートは、世界のワクチンアジュバント市場の現状と将来展望を包括的に分析し、グローバルの主要地域における開発動向の綿密な調査を通じて、読者に包括的な市場分析を提示するものであります。市場の全体像を把握するために、プレイヤー、地域、製品タイプ、最終産業を網羅した多角的な分析を提供しています。さらに、世界市場のトッププレイヤーを特定し、プロファイルを作成するとともに、製品タイプや用途/最終産業に基づいてワクチンアジュバント市場を細分化しています。この分類と応用により、市場の構造とダイナミクスをより深く理解することができ、情報に基づいた意思決定と戦略立案が可能になります。
一. 生産面では、2019年から2024年まで、そして2030年までの予測として、メーカー別、地域別（地域レベル、国レベル）のワクチンアジュバント生産量、成長率、市場シェアを調査している。

二. 消費面では、ワクチンアジュバントの売上高を地域別（地域レベル・国レベル）、企業別、種類別、用途別に焦点を当てています。2019年から2024年まで、2030年までの予測。

三.主要メーカーのワクチンアジュバント売上高、収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界のワクチンアジュバント市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。

四.本ワクチンアジュバントのレポートでは関係者が市場の競争状況を包括的に理解し、事業戦略や市場戦略を的確に立てるのに役立つ洞察を提供することを目的としています。 売上高、成長動向、生産技術、用途、エンドユーザー産業の市場規模に関する詳細な評価と予測を提供し、意思決定者に強力なデータサポートを提供します。

章の概要
第1章：ワクチンアジュバントのレポート範囲、各市場セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメントのエグゼクティブサマリー（タイプ別およびアプリケーション別など）を紹介します。市場の現状と、短期から中期、および長期的な進化の可能性を高度に見ることができます。（2019～2030）
第2章： ワクチンアジュバントの世界と主要生産者（地域／国）の生産／アウトプット。各生産者の生産量と今後6年間の発展可能性を定量的に分析しています。（2019～2030）
第3章：世界、地域、国レベルにおけるワクチンアジュバントの売上（消費）、収益。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界の各国の市場発展、将来の発展の見通し、市場空間を紹介します。（2019～2030）
第4章ワクチンアジュバントメーカーの競争状況、価格、売上高、収益、市場シェアと業界ランキング、最新の開発計画、合併、買収情報などの詳細分析。（2019～2024）
第5章：ワクチンアジュバントの各市場セグメントの売上高、収益、平均価格、および開発可能性をカバーした種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの売上高、収益、平均価格、発展の可能性をカバーし、読者が異なる下流市場でのブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第7章：北米（米国・カナダ）：タイプ別、用途別、国別、セグメント別の売上高、収益。（2019～2030）
第8章：ヨーロッパ：タイプ別、用途別、国別、セグメント別の売上高と収益。（2019～2030）
第9章：中国：タイプ別、アプリケーション別、セグメント別の売上高、収益。（2019～2030）
第10章：アジア（中国を除く）：タイプ別、用途別、地域別、セグメント別の売上高、収益。（2019～2030）
第11章：中東、アフリカ、中南米：タイプ別、用途別、国別、セグメント別の売上高、収益。（2019～2030）
第12章：ワクチンアジュバントの主要メーカーの概要を提供し、製品の説明と仕様、ワクチンアジュバントの売上高、収益、価格、粗利益率、最近の発展など、市場の主要企業の基本的な状況を詳細に紹介します。（2019～2024）
第13章：産業チェーン、販売チャネル、主要原材料、販売代理店および顧客の分析。
第14章：ワクチンアジュバントの市場動態、市場の最新の動向、市場の推進要因と制約要因、業界内のメーカーが直面する課題とリスク、業界内の関連政策の分析を紹介します。
第15章：レポートの要点と結論。

An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities, and have been used in human vaccines for more than 90 years. And many vaccines also contain an adjuvant or adjuvant combination: these are substances added to vaccines specifically because of their immune enhancing effects. Adjuvants were initially used to counter the poor immunogenic potential of highly purified antigens. In recent years their role has expanded as our understanding of the immunology of vaccination has grown.
The global Vaccine Adjuvants market is projected to grow from US$ 682 million in 2024 to US$ 1125 million by 2030, at a Compound Annual Growth Rate (CAGR) of 8.7% during the forecast period.
The vaccine adjuvants market is driven by the increasing need for more effective and long-lasting vaccines. Adjuvants are substances added to vaccines to enhance the body’s immune response, making vaccines more effective, especially in cases where the antigen alone may not provide sufficient protection. The growing prevalence of infectious diseases and the rising demand for vaccines to address new and emerging pathogens, such as COVID-19 variants, are fueling the development and adoption of advanced adjuvants. Additionally, ongoing research and development in immunology and biotechnology are leading to the creation of novel adjuvants that improve vaccine efficacy and safety.
One of the main challenges in the vaccine adjuvants market is the complexity and cost associated with developing and producing new adjuvants. The process requires significant investment in research and development, as well as rigorous testing to ensure safety and effectiveness. Additionally, there are regulatory hurdles that must be overcome, as new adjuvants need to meet stringent guidelines before they can be approved for use. Public concerns about vaccine safety and the potential for adverse reactions to adjuvants also pose challenges, as any negative perceptions can impact vaccine acceptance and adoption.
Report Includes
This report presents an overview of global market for Vaccine Adjuvants, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Vaccine Adjuvants, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Vaccine Adjuvants, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Vaccine Adjuvants sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Vaccine Adjuvants market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Vaccine Adjuvants sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including GSK, CSL Limited, Croda, SEPPIC, Sanofi, Zhifei Biological, Escon, Huanuotai Biological, Rico Bio, SDA BIO, etc.

Market Segmentation
By Company
    GSK
    CSL Limited
    Croda
    SEPPIC
    Sanofi
    Zhifei Biological
    Escon
    Huanuotai Biological
    Rico Bio
    SDA BIO
    SPI Pharma
    Phibro Animal Health
    Vertellus

Segment by Type
    Emulsion Adjuvants
    Mineral Adjuvants
    Others

Segment by Application
    Human Vaccine
    Veterinary Vaccine

Segment by region
    US & Canada
        U.S.
        Canada
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        U.K.
        Italy
        Russia

Middle East, Africa, Latin America
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Vaccine Adjuvants in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Vaccine Adjuvants manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Vaccine Adjuvants sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.

List of Tables
 Table 1. Global Vaccine Adjuvants Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
 Table 2. Major Manufacturers of Emulsion Adjuvants
 Table 3. Major Manufacturers of Mineral Adjuvants
 Table 4. Major Manufacturers of Others
 Table 5. Global Vaccine Adjuvants Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
 Table 6. Global Vaccine Adjuvants Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 7. Global Vaccine Adjuvants Revenue by Region (2019-2024) & (US$ Million)
 Table 8. Global Vaccine Adjuvants Revenue by Region (2025-2030) & (US$ Million)
 Table 9. Global Vaccine Adjuvants Revenue Market Share by Region (2019-2024)
 Table 10. Global Vaccine Adjuvants Revenue Market Share by Region (2025-2030)
 Table 11. Global Vaccine Adjuvants Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (MT)
 Table 12. Global Vaccine Adjuvants Sales by Region (2019-2024) & (MT)
 Table 13. Global Vaccine Adjuvants Sales by Region (2025-2030) & (MT)
 Table 14. Global Vaccine Adjuvants Sales Market Share by Region (2019-2024)
 Table 15. Global Vaccine Adjuvants Sales Market Share by Region (2025-2030)
 Table 16. Global Vaccine Adjuvants Sales by Manufacturers (2019-2024) & (MT)
 Table 17. Global Vaccine Adjuvants Sales Share by Manufacturers (2019-2024)
 Table 18. Global Vaccine Adjuvants Revenue by Manufacturers (2019-2024) & (US$ Million)
 Table 19. Global Vaccine Adjuvants Revenue Market Share by Manufacturers (2019-2024)
 Table 20. Global Key Players of Vaccine Adjuvants, Industry Ranking, 2021 VS 2022 VS 2023
 Table 21. Vaccine Adjuvants Price by Manufacturers (2019-2024) & (USD/Kg)
 Table 22. Global Vaccine Adjuvants Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 23. Global Vaccine Adjuvants by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vaccine Adjuvants as of 2023)
 Table 24. Global Key Manufacturers of Vaccine Adjuvants, Manufacturing Base Distribution and Headquarters
 Table 25. Global Key Manufacturers of Vaccine Adjuvants, Product Offered and Application
 Table 26. Global Key Manufacturers of Vaccine Adjuvants, Date of Enter into This Industry
 Table 27. Mergers & Acquisitions, Expansion Plans
 Table 28. Global Vaccine Adjuvants Sales by Type (2019-2024) & (MT)
 Table 29. Global Vaccine Adjuvants Sales by Type (2025-2030) & (MT)
 Table 30. Global Vaccine Adjuvants Sales Share by Type (2019-2024)
 Table 31. Global Vaccine Adjuvants Sales Share by Type (2025-2030)
 Table 32. Global Vaccine Adjuvants Revenue by Type (2019-2024) & (US$ Million)
 Table 33. Global Vaccine Adjuvants Revenue by Type (2025-2030) & (US$ Million)
 Table 34. Global Vaccine Adjuvants Revenue Share by Type (2019-2024)
 Table 35. Global Vaccine Adjuvants Revenue Share by Type (2025-2030)
 Table 36. Vaccine Adjuvants Price by Type (2019-2024) & (USD/Kg)
 Table 37. Global Vaccine Adjuvants Price Forecast by Type (2025-2030) & (USD/Kg)
 Table 38. Global Vaccine Adjuvants Sales by Application (2019-2024) & (MT)
 Table 39. Global Vaccine Adjuvants Sales by Application (2025-2030) & (MT)
 Table 40. Global Vaccine Adjuvants Sales Share by Application (2019-2024)
 Table 41. Global Vaccine Adjuvants Sales Share by Application (2025-2030)
 Table 42. Global Vaccine Adjuvants Revenue by Application (2019-2024) & (US$ Million)
 Table 43. Global Vaccine Adjuvants Revenue by Application (2025-2030) & (US$ Million)
 Table 44. Global Vaccine Adjuvants Revenue Share by Application (2019-2024)
 Table 45. Global Vaccine Adjuvants Revenue Share by Application (2025-2030)
 Table 46. Vaccine Adjuvants Price by Application (2019-2024) & (USD/Kg)
 Table 47. Global Vaccine Adjuvants Price Forecast by Application (2025-2030) & (USD/Kg)
 Table 48. US & Canada Vaccine Adjuvants Sales by Type (2019-2024) & (MT)
 Table 49. US & Canada Vaccine Adjuvants Sales by Type (2025-2030) & (MT)
 Table 50. US & Canada Vaccine Adjuvants Revenue by Type (2019-2024) & (US$ Million)
 Table 51. US & Canada Vaccine Adjuvants Revenue by Type (2025-2030) & (US$ Million)
 Table 52. US & Canada Vaccine Adjuvants Sales by Application (2019-2024) & (MT)
 Table 53. US & Canada Vaccine Adjuvants Sales by Application (2025-2030) & (MT)
 Table 54. US & Canada Vaccine Adjuvants Revenue by Application (2019-2024) & (US$ Million)
 Table 55. US & Canada Vaccine Adjuvants Revenue by Application (2025-2030) & (US$ Million)
 Table 56. US & Canada Vaccine Adjuvants Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 57. US & Canada Vaccine Adjuvants Revenue by Country (2019-2024) & (US$ Million)
 Table 58. US & Canada Vaccine Adjuvants Revenue by Country (2025-2030) & (US$ Million)
 Table 59. US & Canada Vaccine Adjuvants Sales by Country (2019-2024) & (MT)
 Table 60. US & Canada Vaccine Adjuvants Sales by Country (2025-2030) & (MT)
 Table 61. Europe Vaccine Adjuvants Sales by Type (2019-2024) & (MT)
 Table 62. Europe Vaccine Adjuvants Sales by Type (2025-2030) & (MT)
 Table 63. Europe Vaccine Adjuvants Revenue by Type (2019-2024) & (US$ Million)
 Table 64. Europe Vaccine Adjuvants Revenue by Type (2025-2030) & (US$ Million)
 Table 65. Europe Vaccine Adjuvants Sales by Application (2019-2024) & (MT)
 Table 66. Europe Vaccine Adjuvants Sales by Application (2025-2030) & (MT)
 Table 67. Europe Vaccine Adjuvants Revenue by Application (2019-2024) & (US$ Million)
 Table 68. Europe Vaccine Adjuvants Revenue by Application (2025-2030) & (US$ Million)
 Table 69. Europe Vaccine Adjuvants Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 70. Europe Vaccine Adjuvants Revenue by Country (2019-2024) & (US$ Million)
 Table 71. Europe Vaccine Adjuvants Revenue by Country (2025-2030) & (US$ Million)
 Table 72. Europe Vaccine Adjuvants Sales by Country (2019-2024) & (MT)
 Table 73. Europe Vaccine Adjuvants Sales by Country (2025-2030) & (MT)
 Table 74. China Vaccine Adjuvants Sales by Type (2019-2024) & (MT)
 Table 75. China Vaccine Adjuvants Sales by Type (2025-2030) & (MT)
 Table 76. China Vaccine Adjuvants Revenue by Type (2019-2024) & (US$ Million)
 Table 77. China Vaccine Adjuvants Revenue by Type (2025-2030) & (US$ Million)
 Table 78. China Vaccine Adjuvants Sales by Application (2019-2024) & (MT)
 Table 79. China Vaccine Adjuvants Sales by Application (2025-2030) & (MT)
 Table 80. China Vaccine Adjuvants Revenue by Application (2019-2024) & (US$ Million)
 Table 81. China Vaccine Adjuvants Revenue by Application (2025-2030) & (US$ Million)
 Table 82. Asia Vaccine Adjuvants Sales by Type (2019-2024) & (MT)
 Table 83. Asia Vaccine Adjuvants Sales by Type (2025-2030) & (MT)
 Table 84. Asia Vaccine Adjuvants Revenue by Type (2019-2024) & (US$ Million)
 Table 85. Asia Vaccine Adjuvants Revenue by Type (2025-2030) & (US$ Million)
 Table 86. Asia Vaccine Adjuvants Sales by Application (2019-2024) & (MT)
 Table 87. Asia Vaccine Adjuvants Sales by Application (2025-2030) & (MT)
 Table 88. Asia Vaccine Adjuvants Revenue by Application (2019-2024) & (US$ Million)
 Table 89. Asia Vaccine Adjuvants Revenue by Application (2025-2030) & (US$ Million)
 Table 90. Asia Vaccine Adjuvants Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 91. Asia Vaccine Adjuvants Revenue by Region (2019-2024) & (US$ Million)
 Table 92. Asia Vaccine Adjuvants Revenue by Region (2025-2030) & (US$ Million)
 Table 93. Asia Vaccine Adjuvants Sales by Region (2019-2024) & (MT)
 Table 94. Asia Vaccine Adjuvants Sales by Region (2025-2030) & (MT)
 Table 95. Middle East, Africa and Latin America Vaccine Adjuvants Sales by Type (2019-2024) & (MT)
 Table 96. Middle East, Africa and Latin America Vaccine Adjuvants Sales by Type (2025-2030) & (MT)
 Table 97. Middle East, Africa and Latin America Vaccine Adjuvants Revenue by Type (2019-2024) & (US$ Million)
 Table 98. Middle East, Africa and Latin America Vaccine Adjuvants Revenue by Type (2025-2030) & (US$ Million)
 Table 99. Middle East, Africa and Latin America Vaccine Adjuvants Sales by Application (2019-2024) & (MT)
 Table 100. Middle East, Africa and Latin America Vaccine Adjuvants Sales by Application (2025-2030) & (MT)
 Table 101. Middle East, Africa and Latin America Vaccine Adjuvants Revenue by Application (2019-2024) & (US$ Million)
 Table 102. Middle East, Africa and Latin America Vaccine Adjuvants Revenue by Application (2025-2030) & (US$ Million)
 Table 103. Middle East, Africa and Latin America Vaccine Adjuvants Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 104. Middle East, Africa and Latin America Vaccine Adjuvants Revenue by Country (2019-2024) & (US$ Million)
 Table 105. Middle East, Africa and Latin America Vaccine Adjuvants Revenue by Country (2025-2030) & (US$ Million)
 Table 106. Middle East, Africa and Latin America Vaccine Adjuvants Sales by Country (2019-2024) & (MT)
 Table 107. Middle East, Africa and Latin America Vaccine Adjuvants Sales by Country (2025-2030) & (MT)
 Table 108. GSK Company Information
 Table 109. GSK Description and Major Businesses
 Table 110. GSK Vaccine Adjuvants Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
 Table 111. GSK Vaccine Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
 Table 112. GSK Recent Developments
 Table 113. CSL Limited Company Information
 Table 114. CSL Limited Description and Major Businesses
 Table 115. CSL Limited Vaccine Adjuvants Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
 Table 116. CSL Limited Vaccine Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
 Table 117. CSL Limited Recent Developments
 Table 118. Croda Company Information
 Table 119. Croda Description and Major Businesses
 Table 120. Croda Vaccine Adjuvants Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
 Table 121. Croda Vaccine Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
 Table 122. Croda Recent Developments
 Table 123. SEPPIC Company Information
 Table 124. SEPPIC Description and Major Businesses
 Table 125. SEPPIC Vaccine Adjuvants Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
 Table 126. SEPPIC Vaccine Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
 Table 127. SEPPIC Recent Developments
 Table 128. Sanofi Company Information
 Table 129. Sanofi Description and Major Businesses
 Table 130. Sanofi Vaccine Adjuvants Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
 Table 131. Sanofi Vaccine Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
 Table 132. Sanofi Recent Developments
 Table 133. Zhifei Biological Company Information
 Table 134. Zhifei Biological Description and Major Businesses
 Table 135. Zhifei Biological Vaccine Adjuvants Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
 Table 136. Zhifei Biological Vaccine Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
 Table 137. Zhifei Biological Recent Developments
 Table 138. Escon Company Information
 Table 139. Escon Description and Major Businesses
 Table 140. Escon Vaccine Adjuvants Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
 Table 141. Escon Vaccine Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
 Table 142. Escon Recent Developments
 Table 143. Huanuotai Biological Company Information
 Table 144. Huanuotai Biological Description and Major Businesses
 Table 145. Huanuotai Biological Vaccine Adjuvants Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
 Table 146. Huanuotai Biological Vaccine Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
 Table 147. Huanuotai Biological Recent Developments
 Table 148. Rico Bio Company Information
 Table 149. Rico Bio Description and Major Businesses
 Table 150. Rico Bio Vaccine Adjuvants Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
 Table 151. Rico Bio Vaccine Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
 Table 152. Rico Bio Recent Developments
 Table 153. SDA BIO Company Information
 Table 154. SDA BIO Description and Major Businesses
 Table 155. SDA BIO Vaccine Adjuvants Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
 Table 156. SDA BIO Vaccine Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
 Table 157. SDA BIO Recent Developments
 Table 158. SPI Pharma Company Information
 Table 159. SPI Pharma Description and Major Businesses
 Table 160. SPI Pharma Vaccine Adjuvants Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
 Table 161. SPI Pharma Vaccine Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
 Table 162. SPI Pharma Recent Developments
 Table 163. Phibro Animal Health Company Information
 Table 164. Phibro Animal Health Description and Major Businesses
 Table 165. Phibro Animal Health Vaccine Adjuvants Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
 Table 166. Phibro Animal Health Vaccine Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
 Table 167. Phibro Animal Health Recent Developments
 Table 168. Vertellus Company Information
 Table 169. Vertellus Description and Major Businesses
 Table 170. Vertellus Vaccine Adjuvants Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
 Table 171. Vertellus Vaccine Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
 Table 172. Vertellus Recent Developments
 Table 173. Key Raw Materials Lists
 Table 174. Raw Materials Key Suppliers Lists
 Table 175. Vaccine Adjuvants Distributors List
 Table 176. Vaccine Adjuvants Customers List
 Table 177. Vaccine Adjuvants Market Trends
 Table 178. Vaccine Adjuvants Market Drivers
 Table 179. Vaccine Adjuvants Market Challenges
 Table 180. Vaccine Adjuvants Market Restraints
 Table 181. Research Programs/Design for This Report
 Table 182. Key Data Information from Secondary Sources
 Table 183. Key Data Information from Primary Sources


List of Figures
 Figure 1. Vaccine Adjuvants Product Picture
 Figure 2. Global Vaccine Adjuvants Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
 Figure 3. Global Vaccine Adjuvants Market Share by Type: 2023 & 2030
 Figure 4. Emulsion Adjuvants Product Picture
 Figure 5. Mineral Adjuvants Product Picture
 Figure 6. Others Product Picture
 Figure 7. Global Vaccine Adjuvants Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
 Figure 8. Global Vaccine Adjuvants Market Share by Application: 2023 & 2030
 Figure 9. Human Vaccine
 Figure 10. Veterinary Vaccine
 Figure 11. Vaccine Adjuvants Report Years Considered
 Figure 12. Global Vaccine Adjuvants Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 13. Global Vaccine Adjuvants Revenue (2019-2030) & (US$ Million)
 Figure 14. Global Vaccine Adjuvants Revenue (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Figure 15. Global Vaccine Adjuvants Revenue Market Share by Region in Percentage: 2023 Versus 2030
 Figure 16. Global Vaccine Adjuvants Revenue Market Share by Region (2019-2030)
 Figure 17. Global Vaccine Adjuvants Sales (2019-2030) & (MT)
 Figure 18. Global Vaccine Adjuvants Sales (CAGR) by Region: 2019 VS 2023 VS 2030 (MT)
 Figure 19. Global Vaccine Adjuvants Sales Market Share by Region (2019-2030)
 Figure 20. US & Canada Vaccine Adjuvants Sales YoY (2019-2030) & (MT)
 Figure 21. US & Canada Vaccine Adjuvants Revenue YoY (2019-2030) & (US$ Million)
 Figure 22. Europe Vaccine Adjuvants Sales YoY (2019-2030) & (MT)
 Figure 23. Europe Vaccine Adjuvants Revenue YoY (2019-2030) & (US$ Million)
 Figure 24. China Vaccine Adjuvants Sales YoY (2019-2030) & (MT)
 Figure 25. China Vaccine Adjuvants Revenue YoY (2019-2030) & (US$ Million)
 Figure 26. Asia (excluding China) Vaccine Adjuvants Sales YoY (2019-2030) & (MT)
 Figure 27. Asia (excluding China) Vaccine Adjuvants Revenue YoY (2019-2030) & (US$ Million)
 Figure 28. Middle East, Africa and Latin America Vaccine Adjuvants Sales YoY (2019-2030) & (MT)
 Figure 29. Middle East, Africa and Latin America Vaccine Adjuvants Revenue YoY (2019-2030) & (US$ Million)
 Figure 30. Global Vaccine Adjuvants Sales Share by Manufacturers (2023)
 Figure 31. The Vaccine Adjuvants Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023
 Figure 32. Global Vaccine Adjuvants Revenue Share by Manufacturers (2023)
 Figure 33. The Top 5 and 10 Largest Manufacturers of Vaccine Adjuvants in the World: Market Share by Vaccine Adjuvants Revenue in 2023
 Figure 34. Global Vaccine Adjuvants Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 35. Global Vaccine Adjuvants Sales Market Share by Type (2019-2030)
 Figure 36. Global Vaccine Adjuvants Revenue Market Share by Type (2019-2030)
 Figure 37. Global Vaccine Adjuvants Sales Market Share by Application (2019-2030)
 Figure 38. Global Vaccine Adjuvants Revenue Market Share by Application (2019-2030)
 Figure 39. US & Canada Vaccine Adjuvants Sales Market Share by Type (2019-2030)
 Figure 40. US & Canada Vaccine Adjuvants Revenue Market Share by Type (2019-2030)
 Figure 41. US & Canada Vaccine Adjuvants Sales Market Share by Application (2019-2030)
 Figure 42. US & Canada Vaccine Adjuvants Revenue Market Share by Application (2019-2030)
 Figure 43. US & Canada Vaccine Adjuvants Revenue Share by Country (2019-2030)
 Figure 44. US & Canada Vaccine Adjuvants Sales Share by Country (2019-2030)
 Figure 45. US Vaccine Adjuvants Revenue (2019-2030) & (US$ Million)
 Figure 46. Canada Vaccine Adjuvants Revenue (2019-2030) & (US$ Million)
 Figure 47. Europe Vaccine Adjuvants Sales Market Share by Type (2019-2030)
 Figure 48. Europe Vaccine Adjuvants Revenue Market Share by Type (2019-2030)
 Figure 49. Europe Vaccine Adjuvants Sales Market Share by Application (2019-2030)
 Figure 50. Europe Vaccine Adjuvants Revenue Market Share by Application (2019-2030)
 Figure 51. Europe Vaccine Adjuvants Revenue Share by Country (2019-2030)
 Figure 52. Europe Vaccine Adjuvants Sales Share by Country (2019-2030)
 Figure 53. Germany Vaccine Adjuvants Revenue (2019-2030) & (US$ Million)
 Figure 54. France Vaccine Adjuvants Revenue (2019-2030) & (US$ Million)
 Figure 55. U.K. Vaccine Adjuvants Revenue (2019-2030) & (US$ Million)
 Figure 56. Italy Vaccine Adjuvants Revenue (2019-2030) & (US$ Million)
 Figure 57. Russia Vaccine Adjuvants Revenue (2019-2030) & (US$ Million)
 Figure 58. China Vaccine Adjuvants Sales Market Share by Type (2019-2030)
 Figure 59. China Vaccine Adjuvants Revenue Market Share by Type (2019-2030)
 Figure 60. China Vaccine Adjuvants Sales Market Share by Application (2019-2030)
 Figure 61. China Vaccine Adjuvants Revenue Market Share by Application (2019-2030)
 Figure 62. Asia Vaccine Adjuvants Sales Market Share by Type (2019-2030)
 Figure 63. Asia Vaccine Adjuvants Revenue Market Share by Type (2019-2030)
 Figure 64. Asia Vaccine Adjuvants Sales Market Share by Application (2019-2030)
 Figure 65. Asia Vaccine Adjuvants Revenue Market Share by Application (2019-2030)
 Figure 66. Asia Vaccine Adjuvants Revenue Share by Region (2019-2030)
 Figure 67. Asia Vaccine Adjuvants Sales Share by Region (2019-2030)
 Figure 68. Japan Vaccine Adjuvants Revenue (2019-2030) & (US$ Million)
 Figure 69. South Korea Vaccine Adjuvants Revenue (2019-2030) & (US$ Million)
 Figure 70. China Taiwan Vaccine Adjuvants Revenue (2019-2030) & (US$ Million)
 Figure 71. Southeast Asia Vaccine Adjuvants Revenue (2019-2030) & (US$ Million)
 Figure 72. India Vaccine Adjuvants Revenue (2019-2030) & (US$ Million)
 Figure 73. Australia Vaccine Adjuvants Revenue (2019-2030) & (US$ Million)
 Figure 74. Middle East, Africa and Latin America Vaccine Adjuvants Sales Market Share by Type (2019-2030)
 Figure 75. Middle East, Africa and Latin America Vaccine Adjuvants Revenue Market Share by Type (2019-2030)
 Figure 76. Middle East, Africa and Latin America Vaccine Adjuvants Sales Market Share by Application (2019-2030)
 Figure 77. Middle East, Africa and Latin America Vaccine Adjuvants Revenue Market Share by Application (2019-2030)
 Figure 78. Middle East, Africa and Latin America Vaccine Adjuvants Revenue Share by Country (2019-2030)
 Figure 79. Middle East, Africa and Latin America Vaccine Adjuvants Sales Share by Country (2019-2030)
 Figure 80. Brazil Vaccine Adjuvants Revenue (2019-2030) & (US$ Million)
 Figure 81. Mexico Vaccine Adjuvants Revenue (2019-2030) & (US$ Million)
 Figure 82. Turkey Vaccine Adjuvants Revenue (2019-2030) & (US$ Million)
 Figure 83. Israel Vaccine Adjuvants Revenue (2019-2030) & (US$ Million)
 Figure 84. GCC Countries Vaccine Adjuvants Revenue (2019-2030) & (US$ Million)
 Figure 85. Vaccine Adjuvants Value Chain
 Figure 86. Vaccine Adjuvants Production Process
 Figure 87. Channels of Distribution (Direct Vs Distribution)
 Figure 88. Bottom-up and Top-down Approaches for This Report
 Figure 89. Data Triangulation
 Figure 90. Key Executives Interviewed